A091990 Stock Overview
Celltrion Healthcare Co., Ltd. engages in the manufacture, processing, and sale of biosimilar and biological medicines to patients around the world. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Celltrion Healthcare Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩75,900.00 |
| 52 Week High | ₩81,400.00 |
| 52 Week Low | ₩53,600.00 |
| Beta | 0.22 |
| 1 Month Change | -3.68% |
| 3 Month Change | 18.04% |
| 1 Year Change | 26.92% |
| 3 Year Change | -43.85% |
| 5 Year Change | 29.67% |
| Change since IPO | 78.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| A091990 | KR Healthcare | KR Market | |
|---|---|---|---|
| 7D | 0% | -4.8% | -3.7% |
| 1Y | 26.9% | -22.0% | -10.4% |
Return vs Industry: A091990 exceeded the KR Healthcare industry which returned 21.2% over the past year.
Return vs Market: A091990 exceeded the KR Market which returned 9.7% over the past year.
Price Volatility
| A091990 volatility | |
|---|---|
| A091990 Average Weekly Movement | 5.6% |
| Healthcare Industry Average Movement | 9.2% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A091990 has not had significant price volatility in the past 3 months.
Volatility Over Time: A091990's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 149 | Hyoung Ki Kim | www.celltrionhealthcare.com |
Celltrion Healthcare Co., Ltd. engages in the manufacture, processing, and sale of biosimilar and biological medicines to patients around the world. Its products include Remsima, a monoclonal antibody biosimilar that is used for rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn's disease, Crohn's disease in children, psoriasis, and psoriatic arthritis; Truxima, which is used for lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis and microscopic polyangiitis, and rheumatoid arthritis; Herzuma that is used for metastatic breast cancer, early breast cancer, and metastatic gastric cancer; and Remsima SC, which is used for rheumatoid arthritis. The company was formerly known as Nexol, Inc. and changed its name to Celltrion Healthcare Co., Ltd.
Celltrion Healthcare Co., Ltd. Fundamentals Summary
| A091990 fundamental statistics | |
|---|---|
| Market cap | ₩11.91t |
| Earnings (TTM) | ₩43.13b |
| Revenue (TTM) | ₩2.22t |
276.1x
P/E Ratio5.4x
P/S RatioIs A091990 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A091990 income statement (TTM) | |
|---|---|
| Revenue | ₩2.22t |
| Cost of Revenue | ₩1.59t |
| Gross Profit | ₩624.94b |
| Other Expenses | ₩581.81b |
| Earnings | ₩43.13b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 274.94 |
| Gross Margin | 28.18% |
| Net Profit Margin | 1.94% |
| Debt/Equity Ratio | 17.1% |
How did A091990 perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield46%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/12 07:13 |
| End of Day Share Price | 2024/01/12 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Celltrion Healthcare Co., Ltd. is covered by 29 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Girish Bakhru | BofA Global Research |
| Hyung Soo Kim | Cape Investment & Securities Co., Ltd. |
| Sunghwan Kim | Credit Suisse |